DOI QR코드

DOI QR Code

Case report : Anterior Open bite after injection of Botulinum Toxin on Masseter Muscles

보툴리눔 톡신 교근 주입 후 발생한 전방 개교합 증례보고

  • Ryu, Ji-won (Department of Oral Medicine, School of Dentistry, Chosun University)
  • 유지원 (조선대학교 치의학전문대학원 구강내과학교실)
  • Received : 2013.10.08
  • Accepted : 2013.10.29
  • Published : 2013.12.30

Abstract

Botulinum neurotoxin(BoNT) is a protease exotoxin produced from Clostridium botulinum. It works by blocking the release of acetylcholine from cholinergic nerve endings causing inactivity of muscles or glands. Recently, the therapeutic use of BoNT have expanded to include a wide range of medical and dental conditions. Botulinum neurotoxin type A(BoNT/A) is used off-label in the orofacial region to treat primary and secondary masticatory and facial muscle spasm, severe bruxism, facial tics, orofacial dyskinesias, dystonias, and hypertrophy of the masticatory muscles. Local hematoma, infection, and persistent pain in the injection site are the site-of-injection side effects. Medication-related side effects are adjacent muscle weakness, slurred speech, an alteration in the character of the saliva, and severe headaches. In most cases, these complications are not persistent and bothersome. We reported a case report of a patient who had transient anterior open bite after BoNT/A injection on masseter muscles to treat the refractory myofascial pain.

References

  1. Persaud R, Garas G, Silva S et al. An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. JRSM Short Rep 2013;4(2):10; Epub 1-9.
  2. Charles PD. Botulinum neurotoxin serotype A: a clinical update on non-cosmetic uses. Am J Health Syst Pharm 2004;61(22 Suppl 6):S11-23.
  3. Glenn T. Clark, Raymond A. Dionne. Orofacial Pain: A guide to medications and management. Oxford, 2012, Wiley-Blackwell, pp. 169-178.
  4. The American Academy of Orofacial Pain. Differential diagnosis and management considerations of temporomandibular disorders. In Okenson JP(Ed). Orofacial pain: guidelines for assessment, diagnosis and management. American Academy of Orofacial Pain. Chicago, 1996, Quintessence Publishing Co.Inc, pp. 113-141.
  5. Ernberg M, Hedenberg-Magnusson B, List T, Svensson P. Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study. Pain 2011;152(9): 1988-1996. https://doi.org/10.1016/j.pain.2011.03.036
  6. List T, Axelsson S. Management of TMD: evidence from systematic reviews and meta-analyses. J Oral Rehabil 2010;37(6): 430-451. https://doi.org/10.1111/j.1365-2842.2010.02089.x
  7. Meunier FA, Lisk G, Sesardic D, Dolly JO. Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol Cell Neurosci 2003;22(4):454-466 https://doi.org/10.1016/S1044-7431(02)00016-7
  8. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26:785-793. https://doi.org/10.1016/j.neuro.2005.01.017
  9. Purkiss J, Welch M, Doward S, Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 2000;59:1403-1406. https://doi.org/10.1016/S0006-2952(00)00260-4
  10. Dodick DW, Turkel CC, DeGryse RE et al. PREEMPT Chronic Migraine Study Group. Onabotulinumtoxin A for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo- controlled phases of the PREEMPT clinical program. Headache 2010;50:921-936. https://doi.org/10.1111/j.1526-4610.2010.01678.x
  11. Simons DG, Travell JG, Simons LS. Travell & Simons's Myofascial Pain and Dysfunction: The Trigger Point Manual. 2nd ed., Baltimore, 1999, Williams & Wilkins, pp. 11-86.
  12. Hong CZ, Simons DG. Pathophysiologic and electrophysiologic mechanism of myofascial trigger points. Arch Phys Med Rehabil 1998;79:863-872. https://doi.org/10.1016/S0003-9993(98)90371-9
  13. Svensson P, List T, Hector G. Analysis of stimulusevoked pain in patients with myofascial temporomandibular pain disorders. Pain 2001;92:399-409. https://doi.org/10.1016/S0304-3959(01)00284-6
  14. Stohler CS. Oral and Maxillofacial Surgery. Temporomandibular Disorders. Philadelphia, 2000, WB Saunders, pp.38-45.
  15. Hong SJ, Yoon CL, Ahn JM, Ryu JW. Treatment of Chronic Myofascial Pain with Botulinum Toxin : Case report. Korean J Oral Med 2010;35(3):221-227
  16. Rivner MH. The neurophysiology of myofascial pain syndrome. Curr Pain Headache Rep 2001;5(5):432-440. https://doi.org/10.1007/s11916-001-0054-6
  17. Brin MF, Fahn S Moskowitz C et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv Neurol 1988;50:599-608.
  18. von Lindern JJ. Type A botulinum toxin in the treatment of chronic facial pain associated with temporo-mandibular dysfunction. Acta Neurol Belg 2001;101:39-41.
  19. Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G. Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study. Cranio 2008;26:126-135.
  20. Nixdorf DR, Heo G, Major PW. Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain. Pain 2002;99:465-473. https://doi.org/10.1016/S0304-3959(02)00240-3
  21. Magdaleno F, Ginestal E. Side effects of stabilization occlusal splints: a report of three cases and literature review. Cranio 2010;28(2):128-135.
  22. Kurtoglu C, Gur OH, Kurkcu M, Sertdemir Y, Guler-Uysal F, Uysal H. Effect of botulinum toxin-A in myofascial pain patients with or without functional disc displacement. J Oral Maxillofac Surg 2008;66:1644-1651. https://doi.org/10.1016/j.joms.2008.03.008